Skip to search formSkip to main contentSkip to account menu

BL22 immunotoxin

Known as: RFB4(dsFv)-PE38 Immunotoxin, BL22 Immunotoxin [RFB4(dsFv)-PE38], BL22 
A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody RFB4 fused to a fragment of Pseudomonas exotoxin-A with potential… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Background and Objective: In recent years, the biological methods have been considered as a most promising candidate for the… 
2014
2014
MSH-PE38KDEL is a chimeric molecule composed of MSH, and fused to a truncated mutant form of Pseudomonas exotoxin (PE38KDEL). Our… 
2012
2012
Background and Aims: One of the emerging therapeutic strategies for targeted treatment of most cancers is the use of immunotoxins… 
2010
2010
6523 Background: CAT-8015 (HA22) contains the Fv domains of the anti-CD22 Mab RFB4 and truncated pseudomonas exotoxin, inducing… 
2008
2008
3001 Background: BL22 is a 63 kDa anti-CD22 recombinant immunotoxin containing truncated Pseudomonas exotoxin. In phase I testing… 
2007
2007
The development of immunotoxin DT386-GMCSF, a fusion protein which bears the N-terminal 386 amino acids of diphtheria toxin and… 
2006
2006
A51 Purine analogs induce long term complete remission in hairy cell leukemia (HCL) patients, but do not appear to be curative… 
2002
2002
Objective To study the effect of conjugate immunotoxin BDI-1-PEA given intravesically on preventing bladder cancer from recurring… 
2002
2002
Objective To express SZ39(ScFv) PE40 in the form of GST fusion protein and prepare a promising way for further investigation of…